Redfield Robert 4

What Happened
Robert Redfield, Chief Medical Officer of Traws Pharma, was awarded 108,854 stock options (reported as a derivative grant) on March 8, 2026. The Form 4 lists the transaction price as $0.00 (i.e., no cash exchanged on the reporting line); this reflects an options award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-08; reported on Form 4 filed 2026-03-10 (no indication of a late filing).
• Transaction type: Award/Grant (derivative stock option) — 108,854 units at $0.00 on the filing.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Options were granted under the Issuer’s 2021 Incentive Compensation Plan (as amended). The award was approved by the issuer’s compensation committee (independent directors) and vests 100% on the first anniversary of the grant date.

Context
This was a compensation award (stock options), not an exercise or market trade; no shares were sold or bought on the open market as part of this filing. Such grants are common executive compensation and do not, by themselves, indicate insider buying or selling intent. The options vest in one year; any future exercise or sale would be reported separately.